Tharimmune, Inc. (NASDAQ:THAR) Short Interest Update

Tharimmune, Inc. (NASDAQ:THAR) was the recipient of a large drop in short interest in December. As of December 31st, there was short interest totalling 60,500 shares, a drop of 32.3% from the December 15th total of 89,300 shares. Approximately 4.2% of the shares of the stock are sold short. Based on an average daily volume of 1,230,000 shares, the days-to-cover ratio is presently 0.0 days.

Hedge Funds Weigh In On Tharimmune

A hedge fund recently bought a new stake in Tharimmune stock. Curi RMB Capital LLC acquired a new stake in Tharimmune, Inc. (NASDAQ:THAR) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 23,620 shares of the company’s stock, valued at approximately $59,000. Curi RMB Capital LLC owned 2.06% of Tharimmune at the end of the most recent reporting period. 1.16% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on THAR shares. RODMAN&RENSHAW raised Tharimmune to a “strong-buy” rating in a report on Friday, December 6th. Rodman & Renshaw assumed coverage on Tharimmune in a research note on Friday, December 6th. They set a “buy” rating and a $17.00 target price for the company.

Tharimmune Stock Up 0.3 %

Shares of NASDAQ:THAR traded up $0.01 during trading on Thursday, hitting $2.00. 11,611 shares of the company were exchanged, compared to its average volume of 42,728. Tharimmune has a 1-year low of $1.84 and a 1-year high of $7.71. The business’s 50 day moving average is $2.21 and its 200-day moving average is $2.63.

Tharimmune Company Profile

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).